FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 stimated average burden ours per response: 0.5

Section 16. F	ox if no longer subjec Form 4 or Form 5 hay continue. <i>See</i> b).	t to STATE	Filed pursuant to Section 16(a) of the Securities Exchange Act of 193 or Section 30(h) of the Investment Company Act of 1940	OMB Number: Estimated average hours per response				
Miles Darr	(First) PHARMACEUT	(Middle)	2. Issuer Name and Ticker or Trading Symbol <u>AGIOS PHARMACEUTICALS, INC.</u> [AGIO] 3. Date of Earliest Transaction (Month/Day/Year) 02/14/2021	5. Relationship of Reporting Person(s) to Issue (Check all applicable) Director 10% Own X Officer (give title Other (sp below) Chief Commercial Officer				
(Street) CAMBRIDG (City)		02139 (Zip)	4. If Amendment, Date of Original Filed (Month/Day/Year)	Line) X Form file	nt/Group Filing (Cher d by One Reporting F d by More than One I	Person		
		Table I - Non-D	erivative Securities Acquired, Disposed of, or Bene	ficially Owned				

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)					5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(
Common stock	02/14/2021		М		8,666	A	\$ <mark>0</mark>	14,541	D	
Common stock	02/16/2021		М		922	A	\$ <mark>0</mark>	15,463	D	
Common stock	02/16/2021		F		2,916	D	\$0	12,547	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

L						·			·						
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code (5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exerc Expiration Da (Month/Day/)	ate	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Restricted stock units	(1)	02/14/2021		м			8,666	(2)	(2)	Common stock	8,666	\$0	17,334	D	
Restricted stock units	(1)	02/16/2021		М			922	(3)	(3)	Common stock	922	\$0	0	D	

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.

2. The restricted stock units were granted on February 14, 2020. Beginning on February 14, 2021, the shares underlying the restricted stock units will vest in three equal annual installments.

3. The restricted stock units were granted on February 16, 2018. Beginning on February 16, 2019, the shares underlying the restricted stock units vest in three equal annual installments.

Remarks:

/s/ William Cook, as Attorney in Fact for Darrin Miles

02/17/2021

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 \ast If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.